Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

🇺🇸 Seeking Alpha (US) —

AI Summary

Rocket Pharmaceuticals discussed an update to its Danon disease program, focusing on the pivotal trial and preliminary clinical data for RP-A501. The provided item is a transcript listing, with no additional trial results or details included.

Markets Health Rocket Pharmaceuticals Danon disease RP-A501 clinical trial gene therapy preliminary data

Read original source →